Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Effect of Minimal Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia

Megan Othus, PhD, Brent L. Wood, MD PhD, Elihu H. Estey, MD, Stephen Petersdorf, MD, Frederick R. Appelbaum, MD, Harry P Erba, MD PhD, Roland B. Walter, MD PhD MS

Blood (2015) 126 (23): 2569.

https://doi.org/10.1182/blood.V126.23.2569.2569

Published: 2015

Journal Articles

Impact Of Cytarabine Dose In The Induction Regimen On The Outcome Of Patients With Newly Diagnosed Acute Myeloid Leukemia With Or Without NPM1 and/Or FLT3 Mutations: A SWOG and MD Anderson Cancer Center Report

Farhad Ravandi, MD, Megan Othus, PhD, Stefan H. Faderl, MD, Derek L. Stirewalt, MD, Sherry R. Pierce, RN, BS, Gautam Borthakur, MD, John Godwin, MD, Jeanne E. Anderson, MD, Stephen Petersdorf, MD, Jorge E. Cortes, MD, Fabiana Ostronoff, MD, Era Pogosova-Agadijanyan, MD, Frederick R. Appelbaum, MD, Hagop M. Kantarjian, MD, Elihu H. Estey, MD

Blood (2013) 122 (21): 2686.

https://doi.org/10.1182/blood.V122.21.2686.2686

Published: 2013

Journal Articles

Prediction Of CR On Reinduction In Patients With Newly Diagnosed Acute Myeloid Leukemia Given Intensive Induction Regimens: A Report From SWOG and Cleveland Clinic

Megan Othus, PhD, Mukherjee Sudipto, MD, Mikkael A. Sekeres, MD, MS, John Godwin, MD, Jeanne E. Anderson, MD, Stephen Petersdorf, MD, Frederick R. Appelbaum, MD, Harry P Erba, MD, Elihu H. Estey, MD

Blood (2013) 122 (21): 3924.

https://doi.org/10.1182/blood.V122.21.3924.3924

Published: 2013

Journal Articles

Evaluation Of Which Patients Get a Second Course Of 3+7 On Cooperative Group Trials For Newly Diagnosed Acute Myeloid Leukemia: A Report From SWOG

Megan Othus, Phd, Frederick R. Appelbaum, MD, Stephen Petersdorf, MD, Harry P Erba, MD, Elihu H. Estey, MD

Blood (2013) 122 (21): 3925.

https://doi.org/10.1182/blood.V122.21.3925.3925

Published: 2013

Journal Articles

NUP98/NSD1 Translocation Further Risk-Stratifies Patients With FLT3/ITD In Acute Myeloid Leukemia: A Report From Children’s Oncology Group and SWOG

Fabiana Ostronoff, MD, Megan Othus, PhD, Robert B. Gerbing, MA, Michael R. Loken, PhD, Susana C Raimondi, PhD, Betsy A. Hirsch, PhD, Beverly J. Lange, MD, Stephen Petersdorf, MD, Jerald Radich, MD, Frederick R. Appelbaum, MD, Alan S. Gamis, MD, MPH, Todd A. Alonzo, PhD, Soheil Meshinchi, MD, PhD

Blood (2013) 122 (21): 488.

https://doi.org/10.1182/blood.V122.21.488.488

Published: 2013

Journal Articles

Prognostic Significance Of NPM1 mutations In The Absence Of FLT3 -ITD in Older Patients With AML: A SWOG Report

Fabiana Ostronoff, MD, Megan Othus, PhD, Soheil Meshinchi, MD, PhD, John E. Godwin, MD, MS, Kenneth J. Kopecky, PhD, Alan List, MD, Vivian G. Oehler, MD, Stephen Petersdorf, MD, Era L. Pogosova-Agadjanyan, Jerald Radich, MD, Cheryl L. Willman, MD, Frederick R. Appelbaum, MD, Derek L. Stirewalt, MD

Blood (2013) 122 (21): 1315.

https://doi.org/10.1182/blood.V122.21.1315.1315

Published: 2013

Journal Articles

The Addition Of Gemtuzumab Ozogamicin (GO) To Induction Chemotherapy Reduces Relapse and Improves Survival In Patients Without Adverse Risk Karyotype: Results Of An Individual Patient Meta-Analysis Of The Five Randomised Trials

Robert K. Hills, MA, MSc, DPhil, Stephen Petersdorf, MD, Elihu H. Estey, MD, Megan Othus, PhD, Frederick R. Appelbaum, MD, Sylvie Castaigne, Herve Dombret, MD, PhD, Sylvie Chevret, Jacques Delaunay, MD, Norbert Ifrah, Jean-Yves Cahn, MD, PhD, Christian Recher, MD, Alan K Burnett, MD

Blood (2013) 122 (21): 356.

https://doi.org/10.1182/blood.V122.21.356.356

Published: 2013

Journal Articles

A Scoring System for Prediction of FLT3 -ITD Positivity in Patients with Newly Diagnosed Acute Myeloid Leukemia.

Blood (2012) 120 (21): 2590.

https://doi.org/10.1182/blood.V120.21.2590.2590

Published: 2012

Journal Articles

Weekly Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia.

Daniel DeAngelo, MD, Wendy Stock, MD, Stephen Petersdorf, MD, Shaw-Ling Wang, Angela Volkert, Erik Vandendries, Anjali Advani, MD

Blood (2012) 120 (21): 2612.

https://doi.org/10.1182/blood.V120.21.2612.2612

Published: 2012

Journal Articles

NCI Common Toxicity Criteria and Mortality After Chemotherapy for Acute Myeloid Leukemia (AML)

Joshua R. Veatch, MD, PhD, Ravinder K Sandhu, MD, Kathleen Shannon-Dorcy, RN, John M. Pagel, MD, PhD, Pamela S. Becker, MD, PhD, Stephen Petersdorf, MD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD

Blood (2012) 120 (21): 1479.

https://doi.org/10.1182/blood.V120.21.1479.1479

Published: 2012

Journal Articles

Declining Rates of Treatment-Related Mortality in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Given “Intensive” Induction Regimens: A Report From the Southwest Oncology Group (SWOG) and MD Anderson Cancer Center (MDA)

Megan Othus, PhD, Hagop M. Kantarjian, MD, Stephen Petersdorf, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Sherry A. Pierce, RN, BS, Harry Paul Erba, MD, PhD, Stefan Faderl, MD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD

Blood (2012) 120 (21): 129.

https://doi.org/10.1182/blood.V120.21.129.129

Published: 2012

Journal Articles

Multicenter Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm

Pamela S. Becker, MD, PhD, Bruno C. Medeiros, MD, Anthony Selwyn Stein, M.D., Frederick R. Appelbaum, MD, Bart L Scott, MD, MS, Colleen Delaney, MD, MSc, Megan Othus, PhD, Paul C. Hendrie, MD, PhD, Kelda M. Gardner, PA-C, Stephen Petersdorf, MD, John M. Pagel, MD, PhD, Roland B. Walter, MD, PhD, Cynthia Parks, Elihu H. Estey, MD

Blood (2012) 120 (21): 3594.

https://doi.org/10.1182/blood.V120.21.3594.3594

Published: 2012

Journal Articles

Prognostic Significance of FLT3 and NPM1 Mutations in Adults of Age 18–60 with De Novo Acute Myeloid Leukemia (AML) on SWOG S0106 Study: A Study by FHCRC and SWOG

Era L. Pogosova-Agadjanyan, Kenneth J. Kopecky, PhD, Stephen Petersdorf, MD, Harry Paul Erba, MD, PhD, Richard M. Stone, MD, Soheil Meshinchi, MD, PhD, Thomas J. Nevill, MD, FRCPC, Jerald P. Radich, MD, Leif Stenke, MD, PhD, Marilyn L Slovak, PhD, Robert K Stuart, MD, Martin S. Tallman, MD, Cheryl L Willman, MD, Rebecca M. Mortensen, Breanna L. Wentz, Frederick R. Appelbaum, MD, Derek L. Stirewalt, MD

Blood (2011) 118 (21): 2520.

https://doi.org/10.1182/blood.V118.21.2520.2520

Published: 2011

Journal Articles

Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia.

Stephen Petersdorf, MD, Kenneth Kopecky, PhD, Robert K Stuart, MD, Richard A. Larson, MD, Thomas J. Nevill, MD, FRCPC, Leif Stenke, MD, PhD, Marilyn L. Slovak, PhD, Martin S. Tallman, MD, Cheryl L. Willman, MD, Harry Erba, MD, Frederick R Appelbaum

Blood (2009) 114 (22): 790.

https://doi.org/10.1182/blood.V114.22.790.790

Published: 2009

Journal Articles

G-CSF Priming, Clofarabine and High Dose Cytarabine (GCLAC) for Relapsed or Refractory Acute Myeloid Leukemia (AML).

Pamela S. Becker, MD, PhD, Elihu Estey, MD, Stephen Petersdorf, MD, Barry E Storer, PhD, Frederick R Appelbaum, MD

Blood (2009) 114 (22): 2068.

https://doi.org/10.1182/blood.V114.22.2068.2068

Published: 2009

Journal Articles

Frequency of Allogeneic Stem Cell Transplant(SCT) in Patients Presenting with Newly-Diagnosed AML or AML at Time of First Salvage Therapy.

Ravinder Sandhu, MD, Stephen Petersdorf, MD, Brenda M. Sandmaier, MD, Paul O'Donnell, MD, PhD, Pamela S. Becker, MD, PhD, H. Joachim Deeg, MD, Frederick R Appelbaum, MD, Elihu H. Estey, MD

Blood (2009) 114 (22): 4332.

https://doi.org/10.1182/blood.V114.22.4332.4332

Published: 2009

Journal Articles

The Mantle Cell Lymphoma International Prognostic Index (MIPI) at Diagnosis Is Associated with Survival of Mantle Cell Lymphoma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation.

Lihua Pan, MD, PhD, Katherine A Guthrie, Ph.D., Brian G. Till, MD, Oliver W. Press, MD, PhD, John M. Pagel, MD, PhD, Stephen Petersdorf, MD, William Bensinger, MD, Leona Holmberg, MD, PhD, David G. Maloney, MD, PhD, Ajay Gopal, MD

Blood (2008) 112 (11): 1143.

https://doi.org/10.1182/blood.V112.11.1143.1143

Published: 2008

Journal Articles

Phase I Trial of Clofarabine and High Dose Cytarabine with G-CSF Priming (G-CLAC) for Relapsed or Refractory Acute Myeloid Leukemia

Pamela S. Becker, MD, PhD, Elihu Estey, MD, Stephen Petersdorf, MD, Paul C. Hendrie, MD, PhD, John M. Pagel, MD, PhD, Derek Stirewalt, MD, Andrei Shustov, MD, Barry E. Storer, PhD, Frederick R. Appelbaum, MD

Blood (2008) 112 (11): 2964.

https://doi.org/10.1182/blood.V112.11.2964.2964

Published: 2008

Journal Articles

A Prospective Multicenter Phase II Study by the Puget Sound Oncology Consortium (PSOC) of Gemcitabine (G), Carboplatin (C), Dexamethasone (D), and Rituximab (R) in Patients with Relapsed/Refractory Lymphoma

Aj ay K Gopal, MD, Oliver W. Press, MD, PhD, Andrei Shustov, MD, Stephen Petersdorf, MD, Ted Gooley, PhD, Jasmine T. Daniels, MD, Mitchell Garrison, MD, George Gjerset, MD, Matthew Lonergan, MD, Anne Murphy, MD, Julie Smith, MD, John M. Pagel, MD, PhD

Blood (2008) 112 (11): 2585.

https://doi.org/10.1182/blood.V112.11.2585.2585

Published: 2008

Journal Articles

Therapy of Myelodysplastic Syndrome (MDS) with Azacitidine Given in Combination with Etanercept: A Phase II Study.

Aaron L. Holsinger, Aravind Ramakrishnan, MD, Barry Storer, PhD, Pamela S. Becker, MD, PhD, Stephen Petersdorf, MD, H. Joachim Deeg, MD, Bart L. Scott, MD

Blood (2007) 110 (11): 1452.

https://doi.org/10.1182/blood.V110.11.1452.1452

Published: 2007

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Effect of Minimal Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia

Impact Of Cytarabine Dose In The Induction Regimen On The Outcome Of Patients With Newly Diagnosed Acute Myeloid Leukemia With Or Without NPM1 and/Or FLT3 Mutations: A SWOG and MD Anderson Cancer Center Report

Prediction Of CR On Reinduction In Patients With Newly Diagnosed Acute Myeloid Leukemia Given Intensive Induction Regimens: A Report From SWOG and Cleveland Clinic

Evaluation Of Which Patients Get a Second Course Of 3+7 On Cooperative Group Trials For Newly Diagnosed Acute Myeloid Leukemia: A Report From SWOG

NUP98/NSD1 Translocation Further Risk-Stratifies Patients With FLT3/ITD In Acute Myeloid Leukemia: A Report From Children’s Oncology Group and SWOG

Prognostic Significance Of NPM1 mutations In The Absence Of FLT3 -ITD in Older Patients With AML: A SWOG Report

The Addition Of Gemtuzumab Ozogamicin (GO) To Induction Chemotherapy Reduces Relapse and Improves Survival In Patients Without Adverse Risk Karyotype: Results Of An Individual Patient Meta-Analysis Of The Five Randomised Trials

A Scoring System for Prediction of FLT3 -ITD Positivity in Patients with Newly Diagnosed Acute Myeloid Leukemia.

Weekly Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia.

NCI Common Toxicity Criteria and Mortality After Chemotherapy for Acute Myeloid Leukemia (AML)

Declining Rates of Treatment-Related Mortality in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Given “Intensive” Induction Regimens: A Report From the Southwest Oncology Group (SWOG) and MD Anderson Cancer Center (MDA)

Multicenter Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm

Prognostic Significance of FLT3 and NPM1 Mutations in Adults of Age 18–60 with De Novo Acute Myeloid Leukemia (AML) on SWOG S0106 Study: A Study by FHCRC and SWOG

G-CSF Priming, Clofarabine and High Dose Cytarabine (GCLAC) for Relapsed or Refractory Acute Myeloid Leukemia (AML).

Frequency of Allogeneic Stem Cell Transplant(SCT) in Patients Presenting with Newly-Diagnosed AML or AML at Time of First Salvage Therapy.

The Mantle Cell Lymphoma International Prognostic Index (MIPI) at Diagnosis Is Associated with Survival of Mantle Cell Lymphoma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation.

Phase I Trial of Clofarabine and High Dose Cytarabine with G-CSF Priming (G-CLAC) for Relapsed or Refractory Acute Myeloid Leukemia

A Prospective Multicenter Phase II Study by the Puget Sound Oncology Consortium (PSOC) of Gemcitabine (G), Carboplatin (C), Dexamethasone (D), and Rituximab (R) in Patients with Relapsed/Refractory Lymphoma

Therapy of Myelodysplastic Syndrome (MDS) with Azacitidine Given in Combination with Etanercept: A Phase II Study.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only